Detailed Information

Cited 8 time in webofscience Cited 8 time in scopus
Metadata Downloads

Enzalutamide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: A retrospective Korean multicenter study in a real-world settingopen access

Authors
Jung, Seung IlKim, Myung SooJeong, Chang WookKwak, CheolHong, Sung KyuKang, Seok HoJoung, Jae YoungLee, Seung HwanYun, Seok JoongKim, Tae-HwanPark, Sung WooJeon, Seong SooKang, MinyongLee, Ji YoulChung, Byung HaHong, Jun HyukAhn, HanjongKim, Choung-SooKwon, Dong Deuk
Issue Date
Jan-2020
Publisher
대한비뇨기과학회
Keywords
Androgen antagonists; Neoplasm metastasis; Prostate neoplasms; Treatment outcome
Citation
Investigative and Clinical Urology, v.61, no.1, pp 19 - 27
Pages
9
Indexed
SCIE
SCOPUS
KCI
Journal Title
Investigative and Clinical Urology
Volume
61
Number
1
Start Page
19
End Page
27
URI
https://scholarworks.korea.ac.kr/kumedicine/handle/2020.sw.kumedicine/1152
DOI
10.4111/icu.2020.61.1.19
ISSN
2466-0493
2466-054X
Abstract
Purpose: This study aimed to evaluate the clinical efficacy of enzalutamide in chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC) patients using real-world data from Korean patients. Materials and Methods: We retrospectively reviewed the medical records of 199 chemotherapy-naive patients with mCRPC at 13 tertiary centers in Korea between 2014 and 2017. All patients received enzalutamide daily and 89 patients received concurrent androgen deprivation therapy (ADT). Results: The median age of the patients was 74 years. Initial results showed that 81.5% of the patients had Gleason score >= 8 and 33.3% of the patients had European Cooperative Oncology Group Performance Status 0. The overall mortality rate was 12%. The median OS was not archieved and 76.7% of patients were alive at 30 months. Median time until PSA progression was 6 months. The overall survival rate at 2 years was significantly higher (84.6% vs. 71.7%, p=0.015) and the duration of PSA progression-free survival was significantly longer (8.0 vs. 4.6 months, p=0.008) in patients receiving concurrent ADT than in those receiving enzalutamide alone. The incidence of adverse events of grade 3 or higher was 1.7%. Multivariate Cox proportional hazard analysis indicated that ADT administered concurrently with enzalutamide significantly improved the overall survival (hazard ratio, 0.346; 95% confidence interval, 0.125-0.958). Conclusions: Enzalutamide is effective and safe for chemotherapy-naive patients with mCRPC. Furthermore, the overall survival was significantly higher in patients receiving enzalutamide and concurrent ADT than in patients receiving enzalutamide alone.
Files in This Item
There are no files associated with this item.
Appears in
Collections
2. Clinical Science > Department of Urology > 1. Journal Articles

qrcode

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Related Researcher

Researcher Kang, Seok Ho photo

Kang, Seok Ho
Anam Hospital (Department of Urology, Anam Hospital)
Read more

Altmetrics

Total Views & Downloads

BROWSE